📰 Registration Document News
Page 78 - Registration Document News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Registration Document. Real-time updates on events, politics, business and more.
February 23, 2023
EQS-News: ABIVAX / Key word(s): MiscellaneousAbivax publishes a prospectus in the context of its capital increase 23.02.2023 / 20:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax publishes a prospectus in the context of its capital increasePARIS, FRANCE, February 23, 2023 – 8:0...
February 23, 2023
With sales of €11.5 billion, strong earnings growth in the year and excellent cash generation including the slowdown in demand in Q4 Acceleration of opportunities in innovative materials for
February 23, 2023
Regulatory News: Upon proposal by the Nominating, Compensation and Corporate Governance Committee, Arkema's (Paris:AKE) Board of Directors at its meeting held on 22 February 2023, decided to propose
February 23, 2023
Targets comfortably achieved Further improvement in profitability Revenue grew 8.9% to more than €5.1 billion. Organic growth1 was 7.6%, exceeding the target revised upward to 7% in October
February 23, 2023
Driven by the strategy of operational excellence and the successful start-up of ElecLink's commercial operations Group Revenue of €1.606 billion (+107%1 EBITDA of €886 million
February 23, 2023
EQS-News: ABIVAX / Key word(s): Miscellaneous Abivax publishes a prospectus in the context of its capital increase 23.02.2023 / 20:00 CET/CEST The issuer is solely responsible for
February 23, 2023
23.02.2023 - PARIS, FRANCE / ACCESSWIRE / February 23, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX) (the Company), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate the immune system to treat patients with ...
February 23, 2023
PARIS, FRANCE / ACCESSWIRE / February 23, 2023 / Abivax (Euronext Paris: FR0012333284 - ABVX) (the "Company"), a Phase 3 clinical-stage biotechnology company focused on developing therapeutics that modulate
February 22, 2023
Record revenue in Q4 (€110.1m) and FY 2022 (€314.0m), total annual growth of 10.0% or stated at constant scope and exchange rates, 5.5% organic1 ? Solid ARR growth up 12.5% vs. Q4 2021, supported by
February 22, 2023
Paris, 22 February 2023, 6:30 p.m. PRESS RELEASE Eramet: Record year with EBITDA above €1.5bn and very strong deleveraging EBITDA1 at €1.5bn and Adjusted EBITDA1,2 at €1.9bn (+58%), including